期刊
KIDNEY INTERNATIONAL
卷 79, 期 8, 页码 871-882出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2010.530
关键词
chronic kidney disease; lipolytic enzymes; pathophysiology; renal lipotoxicity
资金
- JSPS [21591130]
- Takeda Science Foundation
- Grants-in-Aid for Scientific Research [21591130] Funding Source: KAKEN
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome proliferator-activated receptor (PPAR)-alpha, a positive regulator of renal lipolysis. Feeding mice a high-fat diet induced glomerular injury, and treating them with fenofibrate, a PPAR alpha agonist, increased the expression of lipolytic enzymes and reduced lipid accumulation and oxidative stress in glomeruli, while inhibiting the development of albuminuria and glomerular fibrosis. In mice given an overload of free fatty acid-bound albumin to induce tubulointerstitial injury, fenofibrate attenuated the development of oxidative stress, macrophage infiltration, and fibrosis, and enhanced lipolysis in the renal interstitium. Fenofibrate inhibited palmitate-induced expression of profibrotic plasminogen activator inhibitor-1 (PAI-1) in cultured mesangial cells, and the expression of both monocyte chemoattractant protein-1 and PAI-1 in proximal tubular cells along with the overexpression of lipolytic enzymes. Thus, fenofibrate can attenuate lipotoxicity-induced glomerular and tubulointerstitial injuries, with enhancement of renal lipolysis. Whether amelioration of renal lipotoxicity by PPAR alpha agonists will turn out to be a useful strategy against CKD will require direct testing. Kidney International (2011) 79, 871-882; doi: 10.1038/ki.2010.530; published online 26 January 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据